The site will be unavailable from 11:00 PM GMT on Tuesday, 21 July 2026, until 4:00 AM GMT on Wednesday, 22 July 2026, due to scheduled maintenance.

This new plain language summary explains the results of the JAVELIN Bladder 100 study, which looked at avelumab maintenance treatment in people with advanced urothelial cancer.

Read the full article here.

Click here to read the original article on which this summary is based.